NL-OMON48728
Completed
Not Applicable
A single center, randomized study investigating the safety, tolerability, and pharmacokinetics of AZ-009 (Staccato apomorphine) in healthy volunteers and the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZ-009 in subjects with established Parkinson*s Disease. - SAD study of AZ-009 in HV and PD patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Parkinson's disease
- Sponsor
- Alexza Pharmaceuticals Inc.
- Enrollment
- 56
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\* Healthy adult males and females between 18 and 60 years of age, inclusive at the time of signing the informed consent document.
- •\* Female subjects, who are:
- •o Surgically sterile (including bilateral tubal ligation) for at least 3 months prior to screening
- •o Postmenopausal, defined as 1 of the following:
- •\* Last menstrual sequence greater than 12 months prior to screening
- •\* Last menstrual sequence greater than 6 months prior to screening and a serum follicle\-stimulating hormone (FSH) concentration \> 40 mIU/mL
- •o Of childbearing potential (i.e. do not meet the criteria outlined above); subjects must:
- •\* Have a negative urine pregnancy test at Screening and Day \-1, as verified by the study doctor prior to starting study therapy.
- •\* Either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with, effective contraception without interruption with one of the following methods during the study participation up until 90 days after administration of study drug:
- •\* Oral contraceptive medications
Exclusion Criteria
- •\* Any significant medical condition, psychiatric illness or history of depression that could, in the investigator\*s opinion, compromise the subject\*s safety or interfere with the completion of this protocol.
- •\* Any condition including the presence of laboratory abnormalities, which according to the investigator places the subject at unacceptable risk if he/she were to participate in the study.
- •\* Any condition that according to the investigator confounds the ability to interpret data from the study such as a virus, seasonal allergy, concurrent skin rash, etc. on screening or prior to drug treatment phase that may be difficult to discern from further health status changes from an investigational product.
- •\* History of clinically significant central nervous system (e.g., seizures), cardiac, pulmonary (e.g., asthma, COPD), metabolic, renal, hepatic, or gastrointestinal (GI) conditions including gastric bypass or other weight loss surgical procedure; or history of such conditions that, in the opinion of the investigator, may place the subject at an unacceptable risk as a participant in this trial, may interfere with the interpretation of safety and/or tolerability data obtained in the trial, or may interfere with the absorption, distribution, metabolism, or excretion of the study drugs.
- •\* Use of 5HT3 antagonists, drugs known to prolong QTc and use of antihypertensives.
- •\* PR interval \> 220 msec or QRS duration \> 120 msec or QTcF interval \> 450 msec for men and 470 msec for women obtained at screening visit or prior to the first dose of study drug.
- •\* Aspartate transaminase (AST), alanine transaminase (ALT), gamma\-glutamyl transferase (GGT), serum creatinine, or total bilirubin \> 1\.5 upper limit of normal (ULN) at screening or prior to the first dose of study drug. These laboratory tests may be repeated once, if they are abnormal on first screening, and if there is a medical reason to believe the results may be inaccurate. If the repeat test is within the reference range, the subject may be included only if the investigator considers that the previous finding will not compromise the subject\*s safety and will not interfere with the interpretation of safety data.
- •\* Use of non\-prescription medications, including herbal and dietary supplements within 5 days or 5 half\-lives (whichever is longer) prior to the first dose of study drug, (The subject may take paracetamol (\* 2 grams/day) or ibuprofen (\* 1600 mg/day) for up to 48 hours prior to the first dose of study drug. Females may take oral contraceptives. The investigator and study team may review medication use on a case\-by\-case basis to determine if its use would compromise subject safety or interfere with study procedures or data interpretation.
- •\* Use of medication that is inhibitor or inducer of CYP450\-3A4/5 within 3 days of dosing and during the course of the study.
- •\* Consumption of grapefruit, grapefruit juice, star fruit, oranges, orange juice, Seville oranges within 3 days prior to administration of study drug.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
The effect of dietary rapeseed (canola) versus olive oil supplementation on serum lipids, liver enzymes and postprandial inflammatory responses in adipose tissue in obese men.ObesityNutritional, Metabolic, EndocrineISRCTN22073289The Union for the Promotion of Oil and Protein Plants e.V. (Union zur Foerderung von Oel- und Proteinpflanzen e.V) (Germany)20
Not yet recruiting
Not Applicable
A prospective, Single-Centre study to investigate the plaque characteristics of lesions in young Indian patients of =40 yearsHealth Condition 1: I248- Other forms of acute ischemic heart diseaseCTRI/2024/01/061165Dr Nityanand Tripathi
Not yet recruiting
Not Applicable
A prospective, single-centre study to investigate the role of Optical Coherence Tomography and fractional flow reserve for post coronary angioplasty stent optimisatioHealth Condition 1: I208- Other forms of angina pectorisCTRI/2021/04/032543PGIMER
Completed
Not Applicable
A single-center, single-blind study to investigate skin response to sub-therapeutic doses of taspoglutide in GLP-1 analogue naive healthy volunteersNL-OMON34382Hoffmann-La Roche6
Active, not recruiting
Not Applicable
A single-center, randomized, single-blind study in parallel groups to evaluate the efficacy and safety of a new intravenous iron HES preparation as compared to intravenous iron dextran (Cosmofer) in anemic patientsAnemia in chronic kidney diseaseEUCTR2009-014351-72-ATSerumwerk Bernburg